Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, as all of you can see, we are well-positioned for a very exciting 2024 and are encouraged by the progress across our two clinical programs, losmapimod, which has the potential -- which has first-in-market potential for patients with FSHD, and pociredir, which has best-in-class potential for patients living with sickle cell disease |
| In the fourth quarter, we continued to drive forward our two key clinical programs and advance our pre-clinical pipeline and with our cash runway that extends into 2026, I do believe that we are well-positioned to execute our corporate objectives and deliver on key milestones in 2024 and beyond |
| However, they feel that they understand the upside and the benefits of those therapies much better than they do with something like pociredir, which is still in early development |
| Addressing the significant unmet need in the sickle cell community remains a key priority for us, and we are excited to build on this momentum in the years ahead |
| The trial initiated in June 2022 and 15 months later we had surpassed our enrollment expectations, which we believe is a real testament to the high unmet need for this rare disease |
| We believe that pociredir, as an oral HbF inducer, has the potential to provide a differentiated therapeutic option for people living with sickle cell disease |
| We continue to operate from a strong financial position with a cash runway into 2026 |
| And while exciting scientific progress has enabled the advancement and more recently of the approval of gene editing therapeutic approaches, we believe there remains a high unmet need for safe and accessible therapeutic options that are broadly protective of sickle cell symptomatology |
| So, the REACH study is a very well-powered study with the 260 patients that we had enrolled |
| And I think really demonstrating that, and based on our initial experience at the 12-milligram dose, which only went out to six weeks or so, we feel that patients will be able to reach that high 20%, maybe even low 30% range where the disease becomes transformative |
| And we look forward to providing specific guidance on readout of the 12 milligram and 20 milligram cohort as we have additional sites activated and a good basis to project enrollment trajectory |
| As a first-in-class oral small molecule HbF inducer, we believe pociredir has the potential to address a critical unmet need for patients |
| We are looking forward to building on the encouraging clinical data obtained prior to the clinical hold, which demonstrated that pociredir increased total HbF of a magnitude that could translate into a meaningful improvement in disease severity |
| Is that a fair characterization? Iain Fraser Well, I think the validation work on the instrument itself, in terms of the test, retest capabilities, the training process that goes into it, the provision of the technical pieces of it, all of that has been done, and is really quite satisfactory |
| So at this point, let me go a bit deeper and elaborate on the progress we've made toward our goal of delivering transformative therapies to improve the lives of patients with rare genetic diseases |
| We are on track to report top-line data in the fourth quarter of 2024, which will bring us one step closer to delivering the first-ever FDA-approved therapy for FSHD patients |
| Thanks, Dae Gon, I think really good question |
| And this will help to enhance our understanding as well as FDA's understanding of what a change in RWS means for them |
| And we're executing on a plan that we've agreed upon with them that we believe will establish the clinical meaningfulness of the reachable workspace |
| Dae Gon Ha Excellent |
| And I guess, just to wrap up, as you can see from our progress that we've made and our plans for 2024, we remain deeply committed to treat the root causes of genetically defined rare diseases and bringing these transformative therapies to patients |
| Thanks for taking our questions and congrats on all the progress |
| Thanks again to everyone who joined this morning |
| Good morning |
| And before we conclude today's call, as I always do, I would like to extend my sincere appreciation and gratitude to my fellow Fulcrum teammates, to the physicians we work with to advance our clinical studies, and finally, and most importantly to the patients and their families |
| Thanks a lot |
| And please stay safe and healthy |
| Dae Gon Ha Hey, good morning |
| Thank you very much |
| Thanks, Valerie, and thanks to all of you for joining us today |
| Statement |
|---|
| The lower collaboration revenue during 2023 was attributable to the completion of activities under our collaboration agreement with Acceleron, which terminated in October 2022, and due to a decrease in revenues under our collaboration agreement with MyoKardia as we completed our research services during the fourth quarter of 2023 |
| I think the important pieces to point out here are, number one, that reachable workspace has been shown previously, prior to Fulcrum's involvement, that FSHD patients exhibit a decline in their reachable workspace over time |
| FSHD is characterized by a slow but relentless loss of muscle function year after year, resulting in significant impairment of upper extremity muscle function and mobility |
| And for the fourth quarter of 2023, Fulcrum reported a net loss of $24.8 million compared to $26.1 million for the same period in 2022 |
| And as I say, probably most importantly, it's that documentation of the decline experienced by these patients, and that's what the patients report is this inevitable decline over time |
| As a result, many patients are unable to perform daily life activities that you and I take for granted, such as reaching for a cup of coffee, reaching for a cup in the kitchen cabinet, brushing your teeth, feeding yourself, even practicing good hygiene |
| Please refer to Fulcrum's most recent filing with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business |
| Not a lot of mortality, but high morbidity |
| The net loss was $97.3 million for the year ended December 31, 2023 compared to $109.9 million in 2022 |
| Alex, have you guys actually started some pre-commercialization work with the payers specifically? I think there was quite a bit of questions around physicians and their comfort as well as the regulators |
Please consider a small donation if you think this website provides you with relevant information